Randomized Clinical Trial of Açaí Palm Berry Extract as an Intervention in Patients Diagnosed With COVID-19
试验速览
- 阶段
- 2 期
- 入组人数
- 480
- 试验地点
- 4
- 主要终点
- 7-point ordinal symptom scale
研究概览
简要总结
The Açaí trial will be testing if the açaí berry extract, a safe natural product with anti-inflammatory properties, can be used as a treatment option in adult patients with COVID-19 in the community.
详细描述
The current COVID-19 pandemic is caused by the novel coronavirus (SARS-Cov-2). The virus origins have been studied and evidence so far suggests it originates in bats, with spread to humans likely mediated by an intermediate mammalian. Bats have a dampened Nod-like receptor family, pyrin-containing 3 (NLRP3)-mediated inflammation. Dampening NLRP3-mediated inflammation has been associated with the asymptotic viral status, therefore it is plausible that the pathogenic inflammatory response of SARS-CoV-2 might be associated with activation of NLRP3 inflammasome. Data show that the natural extract of Açaí Palm Berry (Euterpe oleracea Mart.) is a potent inhibitor of NLRP3. This is a safe, inexpensive, and readily available natural health supplement which could be a rapid response treatment intervention for patients with COVID-19.
Our primary objective is to establish whether açai palm berry extract (Euterpe oleracea), given to community-dwelling adult patients diagnosed with COVID-19, compared to placebo, improves outcomes over 30 days on the 7-point ordinal scale described by Cao et al, and which is being used widely in COVID-19 trials with the aim of harmonizing endpoints. This study will be a prospective, double-blinded, placebo-controlled, randomized, multicentre clinical trial of Açaí Palm Berry extract in adult patients tested positive for SARS-Cov-2 in the last 7 days and that are currently being treated in the outpatient setting. The intervention group will receive 3 capsules of 520mg (one capsule every eight hours) of Acai Palm Berry extract (Nature's Way, NPN80038874) for 30 days. The non-intervention group will receive placebo pills, on top of standard clinical care. Our main endpoint will be the 7-point ordinal scale.
This project has the benefit of offering a safe and widely used natural extract as a potential treatment strategy to decrease inflammation and improve disease outcomes in patients with COVID-19. With no vaccine currently available, the search for effective treatments is a timely approach. The potential impact of such a therapeutic agent, if effective, can be quite vast given that it can be readily used by anyone and, most importantly, is affordable in many countries.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Double blinding, using placebo pills.
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults over 40 years of age; and
- •Mild to moderate symptoms including fever, dry cough, and tiredness; and
- •Tested positive for SARS-Cov-2, via virological diagnosis (PCR), in the last 7 days; and
- •Not hospitalized at the time of randomization, with no limitations on activities; and
- •Willingness to complete questionnaires and records associated with the study.
排除标准
- •Hospitalized patients at the time of enrollment; or
- •Known allergy to study medication or its non-medicinal ingredients; or
- •Currently taking açai extract or juice; or
- •Chronic severe renal impairment (creatinine clearance <30 mL/min or on renal replacement therapy); or
- •Pregnant or breastfeeding patients; or
- •Women who are planning to become pregnant during the study; or
- •End-stage cancer or patients in whom imminent demise is anticipated and there is no commitment to active ongoing intervention; or
- •Unable to provide informed consent; or
- •Patients taking antiplatelet/blood-thinning medication; or
- •Patients with unstable metabolic disease/chronic diseases/ diseases with any comorbidities and/or any serious medical condition or abnormality of clinical laboratory tests that precludes the patient's safe participation in and completion of the study or puts them in a greater risk of developing severe symptoms (e.g. Individuals with an acute infectious disease, immune-compromised, self-reported confirmation of HIV, other lung diseases such as asthma, emphysema, neurological conditions); or
- •Patients who participated in other clinical research studies 30 days prior to screening; or
- •Patients who are participating in another clinical trial at the same time.
结局指标
主要结局
7-point ordinal symptom scale
时间窗: 30 days
Symptom comparison between patients from the treatment vs control group, using an ordinal symptom scale based on the WHO scale. Patients who were hospitalized will be classified according to their worst score over 30 days and non-hospitalized patients according to their score at 30 days.
次要结局
- All-cause mortality(30 days)
- Need for hospitalization(30 days)
- The composite of all-cause mortality and need for mechanical ventilation(30 days)
- The composite of all-cause mortality and hospitalization(30 days)
- Need for mechanical ventilation(30 days)
研究者
Michael Farkouh
Chair & Director, Peter Munk Centre of Excellence in Multinational Clinical Trials
University Health Network, Toronto